POINT Biopharma Confirms No Delays to SPLASH Trial Due to Recent Global Lutetium Supply Interruption
POINT’s industry-leading radioisotope supply chain enabled company to avoid delays INDIANAPOLIS, March 22, 2022 (GLOBE…
News
Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy
Outside research reports that immune checkpoint therapy of patients with ovarian clear cell carcinomas with…
CinCor Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected…
Nuvectis Pharma, Inc. Reports Fiscal Year 2021 Financial Results and Business Highlights
Completed Initial Public Offering in February 2022, Raising $16.0 million in Gross Proceeds Initiated Phase…
BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure
New Procedure Reimbursement Code Expected to Enhance Study Performance for Clinical Centers Participating in the…
Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference
BOSTON, March 22, 2022 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company…
Pharvaris Announces Preclinical Pharmacological Data for Small Molecule PHA121 Published in International Immunopharmacology
Data demonstrate PHA121 to be a potent human bradykinin B2 receptor antagonist ZUG, Switzerland, March…
Reviva Pharmaceuticals Holdings, Inc. to Participate at the Maxim Virtual Growth Conference
CUPERTINO, Calif., March 22, 2022 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva”…
Impel NeuroPharma to Present Trudhesa™ Data at 2022 Scientific Meeting of American Academy of Neurology
New Data Suggests Rapid, Sustained, and Consistent Migraine Relief with Trudhesa Treatment New Analysis Considers…
Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a…
Universe Pharmaceuticals INC Authorized as The International Branch of National Engineering Technology Research Center
Ji’an, Jiangxi, China, March 22, 2022 (GLOBE NEWSWIRE) — Universe Pharmaceuticals INC (the “Company”) (Nasdaq:…
Kane Biotech Successfully Completes Safety and Biocompatibility Studies for DispersinB® Wound Gel in Preparation for Human Clinical Trials
DispersinB® wound gel accelerates wound healing WINNIPEG, Manitoba, March 22, 2022 (GLOBE NEWSWIRE) — Kane…
Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference
BOTHELL, Wash., March 22, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that…
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
DUBLIN, Ireland, March 22, 2022 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company…
Cognition Therapeutics to Report Fourth Quarter and Full Year 2021 Results
Conference Call and Live Audio Webcast Scheduled for Wednesday, March 30, 2022, 8:00 a.m. ET…
National Survey Reveals Insights into Emotional Impact of Psoriasis and Illuminates Need for New Topical Treatments
Arcutis Skin Insights: Uncovering Psoriasis Survey Arcutis Skin Insights: Uncovering Psoriasis Survey Arcutis Skin Insights:…
Entera Bio to Present at 2022 Maxim Virtual Growth Conference
BOSTON and JERUSALEM, March 22, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a…
Aligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio
Dosing in the first cohort discontinued after multiple reports of ALT flares suggestive of drug-induced…
Iridia Announces Appointment of Thomas H. Cauley, Ph.D. as Vice President, Engineering
Cauley to Lead Development of Company’s Proprietary DNA Data Storage Technology SAN DIEGO, March 22,…
CORRECTION — Statera Biopharma Announces Proposed Underwritten Public Offering
FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) — Statera Biopharma, Inc. (NASDAQ: STAB) (the…